neuroone medical technologies corp - NMTC

NMTC

Close Chg Chg %
0.89 -0.02 -2.59%

Pre-Market

0.87

-0.02 (2.59%)

Volume: 167.10K

Last Updated:

Jan 14, 2026, 4:00 PM EDT

Company Overview: neuroone medical technologies corp - NMTC

NMTC Key Data

Open

$0.90

Day Range

0.86 - 0.90

52 Week Range

0.40 - 1.39

Market Cap

$44.87M

Shares Outstanding

50.41M

Public Float

46.75M

Beta

0.56

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.08

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

372.45K

 

NMTC Performance

1 Week
 
-0.70%
 
1 Month
 
32.32%
 
3 Months
 
5.44%
 
1 Year
 
-17.15%
 
5 Years
 
-93.92%
 

NMTC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About neuroone medical technologies corp - NMTC

NeuroOne Medical Technologies Corp. is a medical technology company, which engages in diagnostics, ablations, and deep brain stimulation technology for brain-related conditions. Its products include Evo Cortical, Evo sEEG, and OneRF. The company was founded by Mark Christianson on August 20, 2009 and is headquartered in Eden Prairie, MN.

NMTC At a Glance

NeuroOne Medical Technologies Corp.
7599 Anagram Drive
Eden Prairie, Minnesota 55344
Phone 1-952-426-1383 Revenue 12.10M
Industry Medical Specialties Net Income -3,605,374.00
Sector Health Technology 2025 Sales Growth 250.353%
Fiscal Year-end 09 / 2026 Employees 18
View SEC Filings

NMTC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.949
Price to Book Ratio 6.283
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -7.409
Enterprise Value to Sales 2.428
Total Debt to Enterprise Value 0.009

NMTC Efficiency

Revenue/Employee 672,094.00
Income Per Employee -200,298.556
Receivables Turnover 9.565
Total Asset Turnover 1.489

NMTC Liquidity

Current Ratio 4.43
Quick Ratio 3.463
Cash Ratio 2.853

NMTC Profitability

Gross Margin 67.297
Operating Margin -34.936
Pretax Margin -29.802
Net Margin -29.802
Return on Assets -44.38
Return on Equity -91.338
Return on Total Capital -49.124
Return on Invested Capital -87.593

NMTC Capital Structure

Total Debt to Total Equity 3.772
Total Debt to Total Capital 3.635
Total Debt to Total Assets 2.453
Long-Term Debt to Equity 2.024
Long-Term Debt to Total Capital 1.95
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Neuroone Medical Technologies Corp - NMTC

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.12M 3.41M 3.45M 12.10M
Sales Growth
+772.60% +60.73% +1.33% +250.35%
Cost of Goods Sold (COGS) incl D&A
241.96K 1.50M 2.37M 3.96M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
226.21K 199.27K 246.79K 261.68K
Depreciation
203.90K 176.95K 224.48K 239.36K
Amortization of Intangibles
22.32K 22.32K 22.32K 22.32K
COGS Growth
-12.30% +518.24% +58.65% +66.70%
Gross Income
1.88M 1.91M 1.08M 8.14M
Gross Income Growth
+5,802.03% +1.79% -43.52% +654.07%
Gross Profit Margin
+88.59% +56.10% +31.27% +67.30%
2022 2023 2024 2025 5-year trend
SG&A Expense
11.25M 13.87M 12.97M 12.37M
Research & Development
4.93M 6.94M 5.07M 4.98M
Other SG&A
6.32M 6.93M 7.90M 7.38M
SGA Growth
+10.41% +23.31% -6.49% -4.62%
Other Operating Expense
- - - -
-
Unusual Expense
- 663.63K 327.09K (784.67K)
EBIT after Unusual Expense
(10.03M) (11.96M) (12.21M) (3.44M)
Non Operating Income/Expense
31.15K 95.76K 125.18K 170.49K
Non-Operating Interest Income
- - 31.00K 200.00K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 228.99K 334.06K
-
Interest Expense Growth
- - -100.00% +45.89%
-
Gross Interest Expense
- - 228.99K 334.06K
-
Interest Capitalized
- - - -
-
Pretax Income
(10.00M) (11.86M) (12.32M) (3.61M)
Pretax Income Growth
-0.52% -18.60% -3.87% +70.73%
Pretax Margin
-471.67% -348.03% -356.74% -29.80%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(10.00M) (11.86M) (12.32M) (3.61M)
Minority Interest Expense
- - - -
-
Net Income
(10.00M) (11.86M) (12.32M) (3.61M)
Net Income Growth
-0.52% -18.60% -3.87% +70.73%
Net Margin Growth
-471.67% -348.03% -356.74% -29.80%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(10.00M) (11.86M) (12.32M) (3.61M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(10.00M) (11.86M) (12.32M) (3.61M)
EPS (Basic)
-0.625 -0.6545 -0.4603 -0.0898
EPS (Basic) Growth
+32.80% -4.72% +29.67% +80.49%
Basic Shares Outstanding
16.00M 18.12M 26.76M 40.15M
EPS (Diluted)
-0.625 -0.6545 -0.4603 -0.0898
EPS (Diluted) Growth
+32.80% -4.72% +29.67% +80.49%
Diluted Shares Outstanding
16.00M 18.12M 26.76M 40.15M
EBITDA
(9.14M) (11.76M) (11.64M) (3.96M)
EBITDA Growth
+9.24% -28.61% +0.98% +65.94%
EBITDA Margin
-431.17% -344.99% -337.11% -32.77%

Snapshot

Average Recommendation BUY Average Target Price 3.00
Number of Ratings 2 Current Quarters Estimate -0.045
FY Report Date 03 / 2026 Current Year's Estimate -0.155
Last Quarter’s Earnings -0.04 Median PE on CY Estimate N/A
Year Ago Earnings -0.09 Next Fiscal Year Estimate -0.11
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 2
Mean Estimate -0.05 -0.04 -0.16 -0.11
High Estimates -0.04 -0.03 -0.14 -0.08
Low Estimate -0.05 -0.05 -0.17 -0.14
Coefficient of Variance -15.71 -35.36 -13.69 -38.57

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Neuroone Medical Technologies Corp - NMTC

Date Name Shares Transaction Value
Oct 2, 2025 David A. Rosa CEO and President; Director 1,156,373 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.89 per share 1,029,171.97
Oct 2, 2025 Steven Mertens Chief Technology Officer 161,329 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.89 per share 143,582.81
Oct 2, 2025 Mark Christanson Business Development Director 230,985 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.89 per share 205,576.65
Apr 8, 2025 Ronald W. McClurg Chief Financial Officer 444,117 Open market or private purchase of non-derivative security Non-derivative transaction at $0.5 per share 222,058.50

Neuroone Medical Technologies Corp in the News